Public Health, Disease Prevention & Wellness

New Study Shows SyMRI’s Potential to Transform Neuroimaging Workflows

SyntheticMR AB (publ) is proud to share the results of a newly published multicenter clinical study in the American Journal of Neuroradiology (AJNR), demonstrating the diagnostic equivalence—and potential advantages—of SyMRI® using the 3D-QALAS method compared to conventional 3D MRI in routine clinical neuroimaging. 

The peer-reviewed study, available here, evaluated a large and diverse patient population across multiple imaging centers. The findings confirmed that 3D synthetic MRI using SyMRI matched conventional MRI in sensitivity, specificity, and diagnostic accuracy. Notably, SyMRI received even higher ratings for image quality. 

“These results underscore the value of SyMRI in real-world clinical practice,” said Johanna Norén, Acting CEO of SyntheticMR. “With diagnostic performance on par with conventional imaging—and with added benefits in workflow efficiency and quantitative imaging—SyMRI has the potential to enhance diagnostic confidence while streamlining MRI protocols.” 

The study highlights SyMRI’s ability—particularly in 3D—to deliver quantitative, multi-contrast images in a single, fast scan without compromising image quality, making it a strong candidate for advancing scalable and standardized neuroimaging practices. 

This clinical evidence further strengthens SyntheticMR’s mission to redefine MRI efficiency, bringing the power of objective, quantitative imaging into routine clinical use. 

For additional information, please contact Johanna Noren, acting CEO, SyntheticMR AB, johanna.noren@syntheticmr.com; +46 70 619 21 00 

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/syntheticmr-ab/r/new-multicenter-study-demonstrates-symri-s-potential-to-transform-clinical-neuroimaging-workflows,c4158230

Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!

Related posts

New Data Show Positive Impact of Oncotype DX® on Patient Care

Business Wire

Ovarian Cancer Costs $70B Annually, Global Study Finds

Business Wire

TriLink BioTechnologies & IVI Sign MOU to Develop mRNA Vaccines

Business Wire